Skip to main content
Year archive

Zelluna ASA — 2021 filings

All 80 regulatory filings released by Zelluna ASA (ULTI) in 2021, sourced directly from the official regulator.

80 Filings
2021 Period
2021 filings (80)
Filing Released Lang
Financial calendar
Report Publication Announcement
2021-12-20 English
First Patient Enrolled in Phase II DOVACC trial of UV1 in Advanced Ovarian Cancer
Legal Proceedings Report
2021-12-15 English
Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma
Regulatory Filings
2021-12-02 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2021-12-02 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2021-12-02 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2021-11-29 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2021-11-29 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2021-11-29 English
Ultimovacs ASA: Mandatory notification for close associate
Director's Dealing
2021-11-25 Norwegian
Ultimovacs ASA: Mandatory notification for close associate
Major Shareholding Notification
2021-11-25 English
Ultimovacs ASA: Third quarter 2021 result presentation
Investor Presentation
2021-11-11 English
Ultimovacs ASA: Third quarter 2021 result presentation
Interim / Quarterly Report Q3 2021
2021-11-11 English
Ultimovacs ASA: Third quarter 2021 result presentation
Report Publication Announcement Q3 2021
2021-11-11 English
Ultimovacs' SITC2021 Data Shows Enduring T cell Response for UV1 Combination in Melanoma
Investor Presentation
2021-11-09 English
Ultimovacs ASA: Invitation to third quarter 2021 results presentation
Report Publication Announcement
2021-11-03 English
Ultimovacs ASA - New share capital registered
Share Issue/Capital Change
2021-11-02 English
Ultimovacs ASA - Transactions by primary insiders and closely associated parties
Director's Dealing
2021-10-27 English
Ultimovacs ASA - Transactions by primary insiders and closely associated parties
Director's Dealing
2021-10-27 English
Ultimovacs ASA - Private placement of new shares successfully placed
Share Issue/Capital Change
2021-10-26 English
Ultimovacs ASA - Contemplated private placement
Capital/Financing Update
2021-10-26 English
Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC)
Regulatory Filings
2021-10-26 English
Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma
Regulatory Filings
2021-10-21 English
Ultimovacs ASA: New share capital registered
Share Issue/Capital Change
2021-10-15 English
Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma
Earnings Release Q2 2021
2021-10-13 English
Ultimovacs ASA: Share capital increase related to exercise of options
Share Issue/Capital Change
2021-10-12 English
Ultimovacs ASA announces Two Key Appointments to the Management Team as the Operations Advances
Board/Management Information
2021-10-08 English
Flagging av nedsalg under 5% eierskap
Major Shareholding Notification
2021-10-04 Norwegian
Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine
Regulatory Filings
2021-10-01 English
Ultimovacs ASA: Second quarter 2021 result presentation
Interim / Quarterly Report Q2 2021
2021-08-20 English
Ultimovacs ASA: Second quarter 2021 result presentation
Investor Presentation
2021-08-20 English
Ultimovacs ASA: Second quarter 2021 result presentation
Earnings Release Q2 2021
2021-08-20 English
Ultimovacs Announces Further Positive Topline Results from Phase I UV1 Cancer Vaccine Combination Study in Metastatic Melanoma
Earnings Release Q2 2021
2021-08-12 English
Ultimovacs ASA: Invitation to second quarter 2021 results webcast presentation
Report Publication Announcement
2021-08-11 English
Ultimovacs announces first patient enrolled in Phase II FOCUS trial of UV1 in head-and-neck cancer
Regulatory Filings
2021-08-05 English
Ultimovacs' Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines
Environmental & Social Information
2021-07-05 English
Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program
Earnings Release Q2 2021
2021-06-04 English
Ultimovacs Announces Publication in The Journal of Translational Medicine on Mechanistic Rationale of UV1 Cancer Vaccine Supporting Phase 2 Study Design in Malignant Mesothelioma
Legal Proceedings Report
2021-06-01 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2021-05-28 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2021-05-25 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2021-05-20 English
Ultimovacs’ UV1 in combination with pembrolizumab shows 60% Objective Response Rate in advanced melanoma Phase I data
Earnings Release Q2 2021
2021-05-19 English
Shareholder Notification: Ultimovacs ASA
Major Shareholding Notification
2021-05-18 English
Shareholder Notification: Ultimovacs ASA
Major Shareholding Notification
2021-05-18 English
Shareholder Notification: Ultimovacs ASA
Major Shareholding Notification
2021-05-18 English
Ultimovacs Publishes Positive Long-term UV1 Data from Phase I Malignant Melanoma Combination Study in Frontiers in Immunology
Regulatory Filings
2021-05-11 English
Ultimovacs ASA: First quarter 2021 result presentation
Interim / Quarterly Report Q1 2021
2021-05-11 English
Ultimovacs ASA: First quarter 2021 result presentation
Investor Presentation Q1 2021
2021-05-11 English
Ultimovacs ASA: First quarter 2021 result presentation
Earnings Release Q1 2021
2021-05-11 English
Ultimovacs to discuss ASCO UV1 Phase I Data in Webcast and Investors Meetings
Investor Presentation
2021-05-10 English
Ultimovacs ASA: Invitation to first quarter 2021 results webcast presentation
Report Publication Announcement
2021-05-05 English
Ultimovacs Announces UV1 Data Presentation at Upcoming 2021 ASCO Annual Meeting
Legal Proceedings Report
2021-04-28 English
Ultimovacs ASA - Share Option Program
Share Issue/Capital Change
2021-04-16 English
Ultimovacs ASA – Annual General Meeting held on 15 April 2021
AGM Information
2021-04-15 Norwegian
Ultimovacs ASA – Annual General Meeting held on 15 April 2021
AGM Information
2021-04-15 Norwegian
Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
Declaration of Voting Results & Voting Rights Announcements
2021-04-12 English
Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021
Legal Proceedings Report
2021-04-10 English
Ultimovacs ASA: Notice of Annual General Meeting on 15 April 2021
AGM Information
2021-03-25 English
Ultimovacs ASA: Notice of Annual General Meeting on 15 April 2021
AGM Information
2021-03-25 English
Ultimovacs ASA: Notice of Annual General Meeting on 15 April 2021
Annual Report FY 2020
2021-03-25 English
Ultimovacs ASA: Notice of Annual General Meeting on 15 April 2021
Remuneration Information
2021-03-25 English
Ultimovacs ASA: Notice of Annual General Meeting on 15 April 2021
Remuneration Information
2021-03-25 English
Ultimovacs ASA: Notice of Annual General Meeting on 15 April 2021
AGM Information
2021-03-25 English
Ultimovacs ASA: Annual Report 2020
Annual Report FY 2020
2021-03-25 Norwegian
Ultimovacs ASA: Annual Report 2020
Report Publication Announcement
2021-03-25 English
Ultimovacs ASA: New share capital registered
Share Issue/Capital Change
2021-03-11 English
Ultimovacs ASA: Share capital increase related to exercise of options
Share Issue/Capital Change
2021-03-08 English
Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine
Investor Presentation
2021-02-18 English
Ultimovacs ASA: Fourth quarter 2020 result presentation
Investor Presentation
2021-02-17 English
Ultimovacs ASA: Fourth quarter 2020 result presentation
Interim / Quarterly Report Q4 2020
2021-02-17 English
Ultimovacs ASA: Fourth quarter 2020 result presentation
Earnings Release Q4 2020
2021-02-17 English
Ultimovacs ASA: Mandatory notification of trade by primary insiders
Director's Dealing
2021-02-11 English
Ultimovacs ASA: Invitation to fourth quarter 2020 results webcast presentation
Report Publication Announcement
2021-02-10 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2021-01-28 English
Ultimovacs Announces NIPU Trial Design Poster Presented at World Conference of Lung Cancer Singapore 2020
Regulatory Filings
2021-01-28 English
Securities Regulation of 29 June 2007 (“STA”) - Disclosure of Significant Shareholding
Major Shareholding Notification
2021-01-20 English
Securities Regulation of 29 June 2007 (“STA”) - Disclosure of Significant Shareholding
Major Shareholding Notification
2021-01-20 English
Financial calendar
Report Publication Announcement
2021-01-20 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2021-01-15 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2021-01-13 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2021-01-12 English